PT-141 Nasal 1mg

$69.99

PT-141 Nasal (1mg) is a non-invasive formulation of Bremelanotide, studied for its central action on melanocortin receptors involved in sexual arousal and libido enhancement. Designed for easy administration in preclinical models.
⚠️ For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

Categories: ,

Description

PT-141 Nasal Spray (1mg) delivers Bremelanotide, a melanocortin receptor agonist, through a convenient intranasal route for use in non-invasive preclinical research. PT-141 is a synthetic analog of α-MSH and primarily targets MC3R and MC4R receptors in the central nervous system, which are associated with sexual desire, motivation, and arousal.

Unlike traditional treatments for sexual dysfunction that act peripherally, PT-141 works through neural pathways—making it especially valuable in research on libido regulation and sexual function. The nasal delivery method provides fast absorption and simplified dosing, useful for time-sensitive behavioral studies.

How PT-141 Nasal Works (Based on Preclinical Research):

  • Activates melanocortin receptors in the brain to influence sexual behavior

  • Bypasses vascular or hormonal pathways for centrally mediated effects

  • Intranasal route allows for rapid, non-invasive delivery

  • Studied for both male and female sexual response mechanisms

Potential Benefits (Based on Preclinical Research):

  • Enhanced sexual arousal and libido in animal models

  • May support erectile function and female sexual motivation

  • Avoids cardiovascular side effects seen with PDE5 inhibitors

  • Ideal for behavioral and neuroendocrine research applications


⚠️ For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory body and is intended solely for laboratory research.

Reviews

There are no reviews yet.

Be the first to review “PT-141 Nasal 1mg”

Your email address will not be published. Required fields are marked *